Arrivent Biopharma, Common Stock Analysis
| AVBP Stock | 18.57 0.29 1.59% |
ArriVent BioPharma, Common is undervalued with Real Value of 23.13 and Target Price of 38.0. The main objective of ArriVent BioPharma, stock analysis is to determine its intrinsic value, which is an estimate of what ArriVent BioPharma, Common is worth, separate from its market price. There are two main types of ArriVent BioPharma,'s stock analysis: fundamental analysis and technical analysis.
The ArriVent BioPharma, stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. ArriVent BioPharma, is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. ArriVent Stock trading window is adjusted to America/New York timezone.
ArriVent |
ArriVent Stock Analysis Notes
About 85.0% of the company shares are held by institutions such as insurance companies. The book value of ArriVent BioPharma, was presently reported as 7.64. The company recorded a loss per share of 2.56. ArriVent BioPharma, had not issued any dividends in recent years. For more info on ArriVent BioPharma, Common please contact the company at 628 277 4836 or go to https://arrivent.com.ArriVent BioPharma, Investment Alerts
| ArriVent BioPharma, generated a negative expected return over the last 90 days | |
| ArriVent BioPharma, has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (80.49 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ArriVent BioPharma, generates negative cash flow from operations | |
| ArriVent BioPharma, has a poor financial position based on the latest SEC disclosures | |
| Over 85.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: ArriVent BioPharma Expected to Announce Earnings on Thursday |
ArriVent Largest EPS Surprises
Earnings surprises can significantly impact ArriVent BioPharma,'s stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-15 | 2024-06-30 | -0.5884 | -0.65 | -0.0616 | 10 | ||
2024-12-31 | 2024-12-31 | -0.7814 | -0.61 | 0.1714 | 21 | ||
2024-03-28 | 2023-12-31 | -1.1 | -0.7 | 0.4 | 36 |
ArriVent Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 645.97 M.ArriVent Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.29) | (0.31) | |
| Return On Capital Employed | (0.57) | (0.59) | |
| Return On Assets | (0.29) | (0.31) | |
| Return On Equity | (0.31) | (0.33) |
Management Efficiency
ArriVent BioPharma, has return on total asset (ROA) of (0.2691) % which means that it has lost $0.2691 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3936) %, meaning that it created substantial loss on money invested by shareholders. ArriVent BioPharma,'s management efficiency ratios could be used to measure how well ArriVent BioPharma, manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/27/2025, Return On Tangible Assets is likely to drop to -0.31. In addition to that, Return On Capital Employed is likely to drop to -0.59. As of 03/27/2025, Total Current Liabilities is likely to drop to about 10.7 M. In addition to that, Liabilities And Stockholders Equity is likely to drop to about 182.6 M| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 8.19 | 8.60 | |
| Tangible Book Value Per Share | 8.19 | 8.60 | |
| Enterprise Value Over EBITDA | (5.90) | (6.20) | |
| Price Book Value Ratio | 3.25 | 3.09 | |
| Enterprise Value Multiple | (5.90) | (6.20) | |
| Price Fair Value | 3.25 | 3.09 | |
| Enterprise Value | 687.8 M | 611.4 M |
ArriVent BioPharma,'s management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Technical Drivers
As of the 27th of March, ArriVent BioPharma, shows the Mean Deviation of 2.25, standard deviation of 2.93, and Risk Adjusted Performance of (0.13). ArriVent BioPharma, technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.ArriVent BioPharma, Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. ArriVent BioPharma, middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for ArriVent BioPharma,. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
ArriVent BioPharma, Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ArriVent BioPharma, insiders, such as employees or executives, is commonly permitted as long as it does not rely on ArriVent BioPharma,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ArriVent BioPharma, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Orbimed Advisors Llc few days ago Discretionary transaction by Orbimed Advisors Llc of 821827 shares of ArriVent BioPharma, subject to Rule 16b-3 | ||
Hillhouse Investment Management, Ltd. over six months ago Acquisition by Hillhouse Investment Management, Ltd. of 555555 shares of ArriVent BioPharma, at 18.0 subject to Rule 16b-3 | ||
Hillhouse Investment Management Ltd over a year ago Conversion by Hillhouse Investment Management Ltd of 3616041 shares of ArriVent BioPharma, | ||
Gordon Carl L over a year ago Conversion by Gordon Carl L of 821827 shares of ArriVent BioPharma, | ||
Gordon Carl L over a year ago Conversion by Gordon Carl L of 469615 shares of ArriVent BioPharma | ||
Jallal Bahija over a year ago Acquisition by Jallal Bahija of 17884 shares of ArriVent BioPharma, subject to Rule 16b-3 | ||
Gordon Carl L over a year ago ArriVent BioPharma exotic insider transaction detected |
ArriVent BioPharma, Outstanding Bonds
ArriVent BioPharma, issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ArriVent BioPharma, uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ArriVent bonds can be classified according to their maturity, which is the date when ArriVent BioPharma, Common has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| ARROW ELECTRS INC Corp BondUS042735BE98 | View | |
| ARROW ELECTRS INC Corp BondUS042735BF63 | View | |
| ARW 295 15 FEB 32 Corp BondUS04273WAC55 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| ARROW ELECTRS INC Corp BondUS042735AK67 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
ArriVent BioPharma, Predictive Daily Indicators
ArriVent BioPharma, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ArriVent BioPharma, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
ArriVent BioPharma, Corporate Filings
8K | 13th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 3rd of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
F4 | 14th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
ASR | 3rd of February 2025 Automatic Shelf Registration Statement under Rule 415 filed with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
8K | 22nd of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 4th of December 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 14th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 12th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
ArriVent BioPharma, Forecast Models
ArriVent BioPharma,'s time-series forecasting models are one of many ArriVent BioPharma,'s stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ArriVent BioPharma,'s historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About ArriVent Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how ArriVent BioPharma, prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ArriVent shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ArriVent BioPharma,. By using and applying ArriVent Stock analysis, traders can create a robust methodology for identifying ArriVent entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Current ArriVent Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ArriVent analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ArriVent analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 38.0 | Strong Buy | 5 | Odds |
Most ArriVent analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand ArriVent stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of ArriVent BioPharma,, talking to its executives and customers, or listening to ArriVent conference calls.
ArriVent Stock Analysis Indicators
ArriVent BioPharma, Common stock analysis indicators help investors evaluate how ArriVent BioPharma, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading ArriVent BioPharma, shares will generate the highest return on investment. By understating and applying ArriVent BioPharma, stock analysis, traders can identify ArriVent BioPharma, position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 150.4 M | |
| Common Stock Shares Outstanding | 33.7 M | |
| Total Stockholder Equity | 257.7 M | |
| Property Plant And Equipment Net | 154 K | |
| Cash And Short Term Investments | 218.9 M | |
| Cash | 74.3 M | |
| Accounts Payable | 3.8 M | |
| Net Debt | -74.1 M | |
| 50 Day M A | 24.5436 | |
| Total Current Liabilities | 17.3 M | |
| Non Current Assets Total | 48 M | |
| Non Currrent Assets Other | 126 K | |
| Stock Based Compensation | 3.2 M |
Additional Tools for ArriVent Stock Analysis
When running ArriVent BioPharma,'s price analysis, check to measure ArriVent BioPharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma, is operating at the current time. Most of ArriVent BioPharma,'s value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma,'s price. Additionally, you may evaluate how the addition of ArriVent BioPharma, to your portfolios can decrease your overall portfolio volatility.